These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 17084249)

  • 21. Effect of torcetrapib on the progression of coronary atherosclerosis.
    Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
    N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver.
    Gauthier A; Lau P; Zha X; Milne R; McPherson R
    Arterioscler Thromb Vasc Biol; 2005 Oct; 25(10):2177-84. PubMed ID: 16123327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia.
    Lee SH; Chung N; Kwan J; Kim DI; Kim WH; Kim CJ; Kim HS; Park SH; Seo HS; Shin DG; Shin YW; Shim WJ; Ahn TH; Ho Yun K; Yoon MH; Cha KS; Choi SW; Han SW; Hyon MS
    Clin Ther; 2007 Nov; 29(11):2365-73. PubMed ID: 18158077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
    Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
    N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
    Zhao L; Jin W; Rader D; Packard C; Feuerstein G
    Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
    Clark RW
    Curr Opin Pharmacol; 2006 Apr; 6(2):162-8. PubMed ID: 16487747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial.
    Barter P
    Am J Cardiol; 2009 Nov; 104(10 Suppl):10E-5E. PubMed ID: 19895939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A low prevalence of coronary heart disease among subjects with increased high-density lipoprotein cholesterol levels, including those with plasma cholesteryl ester transfer protein deficiency.
    Moriyama Y; Okamura T; Inazu A; Doi M; Iso H; Mouri Y; Ishikawa Y; Suzuki H; Iida M; Koizumi J; Mabuchi H; Komachi Y
    Prev Med; 1998; 27(5 Pt 1):659-67. PubMed ID: 9808796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
    Barter PJ; Kastelein JJ
    J Am Coll Cardiol; 2006 Feb; 47(3):492-9. PubMed ID: 16458126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is high HDL cholesterol always good?
    Olsson AG
    Ann Med; 2009; 41(1):11-8. PubMed ID: 19085339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
    Shinkai H
    Expert Opin Ther Pat; 2009 Sep; 19(9):1229-37. PubMed ID: 19663630
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid-lowering therapy does not affect the postprandial drop in high density lipoprotein-cholesterol (HDL-c) plasma levels in obese men with metabolic syndrome: a randomized double blind crossover trial.
    Hajer GR; Dallinga-Thie GM; van Vark-van der Zee LC; Olijhoek JK; Visseren FL
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):870-7. PubMed ID: 18394022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CETP inhibition in cardiovascular risk management: a critical appraisal.
    Dullaart RP; Dallinga-Thie GM; Wolffenbuttel BH; van Tol A
    Eur J Clin Invest; 2007 Feb; 37(2):90-8. PubMed ID: 17217373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anacetrapib: hope for CETP inhibitors?
    Gurfinkel R; Joy TR
    Cardiovasc Ther; 2011 Oct; 29(5):327-39. PubMed ID: 20406242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Higher frequency of abnormal serum angiopoietin-like protein 3 than abnormal cholesteryl ester transfer protein in Japanese hyperalphalipoproteinemic subjects.
    Moon HD; Nakajima K; Kamiyama K; Takanashi K; Sakurabayashi I; Nagamine T
    Clin Chim Acta; 2008 Dec; 398(1-2):99-104. PubMed ID: 18804459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
    Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
    Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
    Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
    Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia.
    Hermann F; Enseleit F; Spieker LE; Périat D; Sudano I; Hermann M; Corti R; Noll G; Ruschitzka F; Lüscher TF
    Thromb Res; 2009; 123(3):460-5. PubMed ID: 18789492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.